Dr Dunn leads a discussion outlining frontline therapies for the treatment of vitiligo. Jeffrey D. Dunn, PharmD, MBA: What therapies are being used? Are they generally covered by different books of ...

It was found that adding NB-UVB light therapy to ruxolitinib (Opzelura) 1.5% cream helped many vitiligo patients who did not respond early to treatment achieve faster and more noticeable skin ...

Experts provide closing pearls regarding the current and prospective treatment landscape of vitiligo. Jeffrey D. Dunn, PharmD, MBA: This has been an awesome discussion. Before we conclude, I’d like to ...

STRATA Skin Sciences announces a study validating its Excimer Laser technology's superiority in treating dermatological conditions compared to traditional UVB sources. STRATA Skin Sciences, Inc.

On July 18, the U.S. Food and Drug Administration (FDA) approved ruxolitinib (Opzelura) cream 1.5 percent as a treatment for the most common form of vitiligo, according to a statement by Incyte, the ...

HORSHAM, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the ...

Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease ...

DelveInsight’s, “Vitiligo Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Vitiligo pipeline landscape. It covers the Vitiligo pipeline drug ...

Last spring, Dominick was at a golf tournament with some friends watching some of the golfers on the putting green. A woman behind him made a comment about how ugly his skin was and that he probably ...

The FINANCIAL — Viticell, the new medical device on the market, offers an innovative treatment for patients with non-progressive vitiligo or post-traumatic hypochromic scars by using autologous grafts ...